Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients.

Juan Vicente-Valor Vicente Escudero-VilaplanaRoberto Collado-BorrellCristina López-LópezCristina Villanueva-BuenoJosé Luis Revuelta-HerreroPaula Ruiz-BrionesBeatriz Somoza-FernándezAna HerranzMaría Sanjurjo

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)

There is increasing evidence that spironolactone behaves as a selective androgen receptor modulator. Strategies to overcome abiraterone-spironolactone interaction could involve the use of eplerenone, although this drug is also controversial. The best strategy should imply a multidisciplinary evaluation by cardiologists and oncologists.

Keyphrases

prostate cancer
benign prostatic hyperplasia
quality improvement
human health
drug induced
climate change
adverse drug
palliative care